Drug vehicle compositions and methods of use thereof
The invention is directed to topical drug vehicle platform compositions for ophthalmological and dermatological use. These compositions comprise a means to sequester tears and an ophthalmological drug. The invention is further directed to methods of treating a spectrum of ocular surface disease epitheliopathies including but not limited to dry eye in a human or mammal. The invention is further directed to contact lenses, punctum plugs, pellets or any other device used to deliver drugs to the surface of the eye, coated or infused with compositions of the invention.
1. A drug vehicle composition consisting of:
from about 0.05% to about 0.09% w/v cyclosporine-A;
about 1.5% w/v polysorbate 80;
about 0.7% w/v poloxamer 407;
about 1.0% w/v poloxamer 188;
about 0.01% w/v polyoxyl castor oil;
from about 1.75% to about 2.5% w/v mannitol;
from about 0.15% to about 0.25% w/v magnesium chloride;
about 1.35% w/v hydroxypropylmethyl cellulose;
about 0.25% w/v sodium chloride;
from about 0.1% to about 0.12% w/v sorbate;
about 4 millimolar citrate buffer; and
water.
2. The composition of claim 1 , wherein the composition has a pH of about 7.0.